Speakers included Kelly McNeil-Posey, director of health economics and outcomes research at Alexion and Sharon Williams, director of U.S. The analysis showed that the strategy of using andexanet alfa for the treatment of factor Xa inhibitor-related ICH is cost-effective, with incremental cost-effectiveness per quality-adjusted life-year gained of 35,872 from a third-party payer perspective and 40,997 from a societal perspective over 20 years. The panel discussion detailed an approved model structure developed with clinical guidance on the cost-effectiveness and budgetary impact of andexanet alfa on selected health outcomes and costs. Cost will remain constant with availability of the Generation 2 product (5500/200 mg vial 27 500 for low dose 49 500 for high dose). In our online survey, 66 of hospitals who had not yet added andexanet alfa to formulary cited cost as a reason. webinar “Andexanet alfa Budget Impact Model” originally broadcast on May 26 has been posted online. Andexanet alfa poses a notable financial challenge for hospitals. The DFW Hospital Council (DFWHC) and Alexion Pharmaceuticals, Inc. Learning Objectives: Andexanet is a FDA-approved specific reversal agent for direct factor Xa inhibitors (dFXaI), however its high cost (24,750-49,500). The wholesale acquisition cost of the standard dose regimen is 24,750, and the high-dose regimen is 49,500.
0 Comments
Leave a Reply. |